Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Amoxicillin + doxycycline** is a combination of two antibiotics from different classes: amoxicillin, a penicillin-type antibiotic, and doxycycline, a tetracycline antibiotic. Amoxicillin acts as a bactericidal agent by inhibiting bacterial cell wall synthesis, leading to cell lysis and death. Doxycycline is bacteriostatic and inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to polypeptide chains. Both drugs are used individually for various bacterial infections; however, their combined use is generally avoided because tetracyclines like doxycycline can reduce the effectiveness of penicillin-type antibiotics such as amoxicillin. This combination may be considered in rare clinical scenarios but is not standard practice due to potential antagonism between the drugs[1][2][3][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Amoxicillin + doxycycline.